triptorelin / Generic mfg. - LARVOL DELTA

Suboptimal ovarian suppression during adjuvant endocrine therapy for premenopausal women with breast cancer: An exploratory analysis of the PREFER and GIM 23 studies (ESMO-BC 2024) - P | "Background Adjuvant endocrine therapy (ET) with exemestane combined with LHRH analog (LHRHa) is standard of care for premenopausal women with hormone receptor-positive breast cancer...65.4% of these patients received chemotherapy, mainly anthracycline plus taxane (93.8%), and 3 patients received adjuvant abemaciclib...Monthly leuprorelin was given in 65% of the cases, while the others received monthly triptorelin...Table: 125P Characteristics N of patients (%) TNM - Stage IA 14 (53.9) IB 3 (11.5) IIA 5 (19.2) IIB 2 (7.7) IIIA 2 (7.7) Grading 1 1 (3.8) 2 18 (69.3) 3 5 (19.2) NA 2 (7.7) Histology Ductal 21 (80.8) Lobular 1 (3.8) Other 4 (15.4) Ki67 <20 12 (46.2) ≥20 14 (53.8) HER2 status 0 12 (46.1) 1+ 5 (19.2) 2+ 2 (7.7) 2+ FISH amplified or 3+ 7 (27) Conclusions In our cohort, almost 5% of premenopausal patients did not achieve ovarian suppression with LHRHa. Oncologists should be aware that serial monitoring of estradiol levels should be performed to address this."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancers (ESMO 2024) - P2 | "To assess the value of ADT, an EORTC-led randomised phase II study was launched. Patients (pts) with untreated R/M/U AR expressing SDC and ADC (cohort A) were randomised to receive CT (cisplatin 75 mg/m2 + doxorubicin 60 mg/m2 or carboplatin AUC 5 + paclitaxel 175 mg/m2 q3 weeks for a maximum of 6 cycles) or ADT (bicalutamide 50 mg once daily + triptorelin 3.75 mg q 28 days until progressive disease (PD)). PFS in R/M/U AR expressing SGCs ADT did not prove superior nor inferior. ADT sensitivity is seen independently of treatment sequence, line and HER2 amplification. ADT combined with CT and/or with HER2 inhibitors, depending on HER2 status, might represent a rational approach for future studies."

Clinical • Late-breaking abstract • Metastases • P2 data • Head and Neck Cancer • Oncology • Salivary Gland Cancer • Solid Tumor • AR

Virginal breast hypertrophy management and the role of Triptorelin (ESPE 2026) - No abstract available

Gynecology

Comparative Efficacy of Quarterly versus Monthly Triptorelin in Chinese Girls with Central Precocious Puberty: A 12-Month Observational Study (ESPE 2026) - No abstract available

Clinical • Observational data • Endocrine Disorders

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. (PubMed, Eur Urol) - "STADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer."

Journal • P3 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Switching Triptorelin from Monthly to Quarterly for Early Puberty: A Multitime-Point Study on Efficacy and Safety (ESPE 2026) - No abstract available

Clinical

Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa). (ASCO 2022) - " Using a prospective cohort study of women with BC diagnosed at age ≤ 40 years, we identified participants with stage I-IV HR+ BC on OFS treatment with leuprolide, goserelin or triptorelin and blood collected 1 year after diagnosis... Of 84 patients who met inclusion criteria, 72 (86%) had stage I-III and 12 (14%) had stage IV BC; 25 were on OFS plus AI and 59 were on OFS plus tamoxifen (TAM)... More than half of young women with ER+ BC had E2 > 2.72 pg/mL on OFS, 91% of whom would not have been detected by standard assays. This may be an area amenable to intervention to improve outcomes in young women. However, larger studies are needed to elucidate the optimal E2 target on OFS and clinical implications of incomplete E2 suppression on ultrasensitive assays."

Clinical • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor

Efficacy and Safety of Triptorelin 3-Month Formulation in Combination with Growth Hormone for Central Precocious Puberty in Chinese Children (ESPE 2026) - No abstract available

Clinical • Combination therapy • Endocrine Disorders

Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial (ASTRO 2024) - "RT dose was 80 Gy in both arms and STADT was monthly triptorelin and daily flutamide for a total duration of 4 months, starting 2 months before irradiation. STADT improves disease-free survival in intermediate and high-risk prostate cancer patients receiving high dose (80 Gy) RT, without any deterioration in the safety profile."

Clinical • Late-breaking abstract • P3 data • Gastrointestinal Disorder • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A window-of-opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC) (IBCSG 67-22; PREcoopERA) (ESMO-BC 2024) - P2 | "Background Adjuvant endocrine therapy (ET) for premenopausal women with ER+/HER2- EBC often includes ovarian function suppression (OFS) via a GnRH or LHRH agonist (LHRHa) plus an aromatase inhibitor (AI) or tamoxifen...Trial design PREcoopERA is a randomized, open-label, 3-arm, WOO trial evaluating the anti-proliferative activity and safety of the oral SERD giredestrant +/- LHRHa triptorelin, as compared to the AI anastrozole + triptorelin...The first woman was enrolled on 25 January 2024. The PREcoopERA trial is sponsored and coordinated by ETOP IBCSG PartnersFoundation in collaboration with F. Hoffmann-La Roche Ltd."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

ENHANCE: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: University College, London | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A window-of-opportunity (WOO) trial of giredestrant +/- LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+/HER2- early breast cancer: PREcoopERA (ESMO-BC 2026) - P2 | "Pts were randomized to 28 days of: G (30 mg daily); GT (Triptorelin 3.75 mg IM D1), or AT (1 mg daily) with tumor re-biopsy on D29. GT and G showed robust anti-proliferative activity, though GT superiority to AT was not demonstrated. G was not non-inferior to GT, suggesting OFS remains relevant to optimal anti-proliferative effect. Regimens were well tolerated."

Clinical • Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • ER • HER-2

Elacestrant alone or in combination with triptorelin in premenopausal women with ER+/HER2- early breast cancer: primary analysis from the phase 2 SOLTI-2104- PremiÈRe trial (SABCS 2025) - P2 | "Ovarian function suppression (OFS) in combination with tamoxifen or aromatase inhibitors improves disease-free survival but has limitations such as toxicity, suboptimal estrogen suppression, and poor adherence. This study provides the first evidence that ELA ± OFS elicits antiproliferative and molecular responses in premenopausal women with ER+/HER2- EBC. Both regimens had comparable and significant reductions in Ki67, CCCA, ROR-P scores, and proliferation gene expression. PremiÈRe trial support the potential role of ELA as a novel ET in this population, potentially sparing the need for OFS."

Clinical • Combination therapy • P2 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST) (clinicaltrials.gov) - P3 | N=126 | Recruiting | Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

New P3 trial • Gynecology

Pubertal Triptorelin Exposure Alters Hypothalamic Reproductive-Metabolic Integration in a Sex-Specific Manner. (PubMed, Biology (Basel)) - "Collectively, these findings demonstrate that pubertal triptorelin treatment induces profound reproductive suppression in both sexes while eliciting sex-specific hypothalamic adaptations in pathways regulating energy homeostasis. This suggests that puberty blockers exert broader neuroendocrine effects beyond the suppression of reproductive maturation."

Journal • Endocrine Disorders

QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Hebei Medical University Fourth Hospital

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Suboptimal ovarian suppression during adjuvant endocrine therapy for premenopausal women with breast cancer: an exploratory analysis of the PREFER and GIM 23 studies (AIOM 2024) - P | "Background : Adjuvant endocrine therapy (ET) with exemestane combined with LHRH analog (LHRHa) is the standard of care for premenopausal women...65.4% of these patients received chemotherapy, mainly anthracycline plus taxane (93.8%), and 3 patients received adjuvant abemaciclib...Monthly leuprorelin was given in 65% of the cases, while the others received monthly triptorelin... in our cohort, almost 5% of premenopausal patients did not achieve ovarian suppression with LHRHa. Oncologists should be aware that serial monitoring of estradiol levels should be performed to address this eventually."

Clinical • Breast Cancer • Oncology • Solid Tumor

Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol. (PubMed, BJU Int) - P=N/A | "Patients aged 18-75 years with high-volume mPCa will receive ADT (triptorelin 15 mg every 3 months), four-six cycles of chemotherapy (docetaxel 75 mg/m2 every 3 weeks), and an ARPI (rezvilutamide 240 mg once daily). PFS and OS will be estimated using Kaplan-Meier curves and compared with the log-rank test. Chinese Clinical Trial Registry: ChiCTR2600121819."

Journal • Genito-urinary Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - P3 | N=2753 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Dec 2033 ➔ Dec 2038

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CD4

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov) - P3 | N=2050 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Nov 2026 ➔ Nov 2031

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Development of a parsimonious predictive model for height gain outcome in children with central precocious puberty following gonadotropin-releasing hormone agonist therapy. (PubMed, Transl Pediatr) - "A retrospective cohort study was conducted enrolling children with CPP treated with triptorelin...The parsimonious model (M2) incorporating IGF-1 SDS and bone age advancement demonstrates robust predictive capability for height gain outcome in children with CPP receiving GnRHa therapy, comparable to the comprehensive model. This model may support early risk stratification and closer growth monitoring in selected patients; however, external validation and confirmation against final adult height outcomes are required before it can inform decisions about adjunctive interventions."

Journal • Endocrine Disorders • IGF1

Peptide Supplements and Their Therapeutic Applications in Sports Medicine. (PubMed, Am J Sports Med) - "Despite promising findings in animal studies, the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials. Documented risks include cardiovascular complications and metabolic dysfunction such as insulin resistance. Because of the lack of robust efficacy and safety data, peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • TMSB4X

ENHANCE: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer (clinicaltrials.gov) - P3 | N=1500 | Not yet recruiting | Sponsor: University College, London

New P3 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Baptist Health South Florida | Trial completion date: Oct 2030 ➔ Feb 2031 | Initiation date: Apr 2026 ➔ Jul 2026 | Trial primary completion date: Oct 2029 ➔ Feb 2030

Trial completion date • Trial initiation date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (clinicaltrials.gov) - P3 | N=27 | Active, not recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial primary completion date: Sep 2026 ➔ Jun 2026

Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor